Eli Lilly and Company (BIT:1LLY)
Italy · Delayed Price · Currency is EUR 686.90
+4.00 (0.59%)
At close: Jul 25, 2025, 5:30 PM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Glucagon | - | Log In | Log In | Log In | Log In | Upgrade |
Glucagon Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Humalog | 2.32B | Log In | Log In | Log In | Log In | Upgrade |
Humalog Growth | 33.44% | Log In | Log In | Log In | Log In | Upgrade |
Humulin | 917.10M | Log In | Log In | Log In | Log In | Upgrade |
Humulin Growth | 9.66% | Log In | Log In | Log In | Log In | Upgrade |
Trajenta | 353.90M | Log In | Log In | Log In | Log In | Upgrade |
Trajenta Growth | -12.49% | Log In | Log In | Log In | Log In | Upgrade |
Oncology | 8.75B | Log In | Log In | Log In | Log In | Upgrade |
Oncology Growth | 24.99% | Log In | Log In | Log In | Log In | Upgrade |
Neuroscience | 1.47B | Log In | Log In | Log In | Log In | Upgrade |
Neuroscience Growth | -53.34% | Log In | Log In | Log In | Log In | Upgrade |
Other Product | 903.00M | Log In | Log In | Log In | Log In | Upgrade |
Other Product Growth | -19.74% | Log In | Log In | Log In | Log In | Upgrade |
Jardiance | 3.34B | Log In | Log In | Log In | Log In | Upgrade |
Jardiance Growth | 28.56% | Log In | Log In | Log In | Log In | Upgrade |
Trulicity | 5.25B | Log In | Log In | Log In | Log In | Upgrade |
Trulicity Growth | -26.00% | Log In | Log In | Log In | Log In | Upgrade |
Basaglar | 676.90M | Log In | Log In | Log In | Log In | Upgrade |
Basaglar Growth | 2.41% | Log In | Log In | Log In | Log In | Upgrade |
Other Cardiometabolic Health | 187.90M | Log In | Log In | Log In | Log In | Upgrade |
Other Cardiometabolic Health Growth | -8.46% | Log In | Log In | Log In | Log In | Upgrade |
Immunology | 4.39B | Log In | Log In | Log In | Log In | Upgrade |
Immunology Growth | 20.58% | Log In | Log In | Log In | Log In | Upgrade |
Other | 100.00K | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Baqsimi | 29.10M | Log In | Log In | Log In | Log In | Upgrade |
Baqsimi Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Mounjaro | 11.54B | Log In | Log In | Log In | Log In | Upgrade |
Mounjaro Growth | 112.08% | Log In | Log In | Log In | Log In | Upgrade |
Zepbound | 4.93B | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
US Revenue | 30.38B | Log In | Log In | Log In | Log In | Upgrade |
US Revenue Growth | 43.91% | Log In | Log In | Log In | Log In | Upgrade |
Europe | 6.92B | Log In | Log In | Log In | Log In | Upgrade |
Europe Growth | 20.60% | Log In | Log In | Log In | Log In | Upgrade |
Japan | 1.81B | Log In | Log In | Log In | Log In | Upgrade |
Japan Growth | 12.36% | Log In | Log In | Log In | Log In | Upgrade |
Other Foreign Countries | 4.27B | Log In | Log In | Log In | Log In | Upgrade |
Other Foreign Countries Growth | 38.21% | Log In | Log In | Log In | Log In | Upgrade |
China | 1.66B | Log In | Log In | Log In | Log In | Upgrade |
China Growth | 12.44% | Log In | Log In | Log In | Log In | Upgrade |
Other
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Revenue Change due to Price | 5.00 | Log In | Log In | Log In | Log In | Upgrade |
Revenue Change due to Price Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Revenue Change due to Volume | 27.00 | Log In | Log In | Log In | Log In | Upgrade |
Revenue Change due to Volume Growth | 64.37% | Log In | Log In | Log In | Log In | Upgrade |
Revenue Change due to FX | - | Log In | Log In | Log In | Log In | Upgrade |
Revenue Change due to FX Growth | - | Log In | Log In | Log In | Log In | Upgrade |